Q3 2025 Ourofino SA Earnings Call Transcript
Key Points
- Ourofino SA (BSP:OFSA3) reported a significant revenue growth of 26% in the third quarter, with a 30% increase in EBITDA.
- The company successfully launched several new products, including a vaccine shot for immunocastration and NexLaner, a pesticide for external parasites.
- Ourofino SA's research and development efforts have been recognized with the FINEP Award for innovation in the Southeast region.
- The company's financial structure remains robust, with long-term debts and a healthy cash flow, generating BRL32 million in cash liquid.
- International operations, particularly in Mexico and Colombia, have shown relevant growth, contributing to the company's strategic expansion in Latin America.
- There was a setback in the production of a key product in Korea, impacting the supply chain and delaying significant volume availability until next year.
- The companionship animals segment experienced slower growth due to market pressures, including high interest rates and reduced consumer spending.
- The company faced margin pressure in the first quarter due to leveraging partnerships and product distribution, which have lower margins compared to line products.
- Despite the overall growth, the company had to make higher investments in stock due to numerous product releases, impacting operational cash flow.
- The companionship animals market entry is new for Ourofino SA, posing challenges in establishing a foothold and achieving significant growth in this segment.
Good morning, everyone. Welcome to this conference of results in the third trimester of 2025. My name is Marcelo, I'm the CFO of the company and alongside with Kleber Gomes, our CEO, we're going to do this conference here to bring you the main highlights of the company in the first nine months of the year and the third trimester; talk a little bit about the results, the financial part of it, what was the performances in the businesses, the cash flow, how is our financial structure now. And by the end of this section, we're going to have a space for questions and answers.
For this first part in our conference here, I'm going to let Kleber talk. He's going to start talking about the main events and releases in this trimester that supported the investments in the company. So Kleber, good morning.
Hello, everybody. Good morning, everyone. Can you hear me well? All good then.
Well, we're approaching the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
